Parvus Therapeutics
CA - South SFBiotechnology
Focus: Parvus Therapeutics is a South San Francisco-based biotech company founded in 2004, specializing in peptide-MHC-coated nanoparticle immunotherapy. The company operates at early clinical stage with a focused pipeline in autoimmune and inflammatory diseases.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
Open Jobs
0
About Parvus Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Parvus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Parvus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT06798454Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
Phase 1Help build intelligence for Parvus Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.